Travere Therapeutics saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an increase from 73 to 88.
Risk Management In The Stock Market: How Much Money To Invest Now
IBD's unique rating measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners tend to have an RS Rating of over 80 as they begin their biggest runs.
Travere Therapeutics is building a cup without handle with a 22.07 buy point. See if the stock can break out in heavy volume.
Travere Therapeutics posted 0% earnings growth in its most recent report, while sales growth came in at 111%.
Travere Therapeutics earns the No. 27 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
